About the dataset

Primary description: Depression treatment prediction

Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) is a 12-week randomized clinical trial for treatment-naïve major depressive disorder (MDD). Participants fall into one of three treatment arms including escitalopram, duloxetine, or cognitive behavioral therapy (CBT). If remission is not achieved, the participant undergoes a second phase of monotherapy. CBT is added to for the users in the escitalopram or duloxetine arms, or escitalopram is added for those in the CBT arm. MRI is obtained at baseline and week 12. For more information, see https://doi.org/10.1186/s12888-022-04509-7.

The study is part of the COORDINATE-MDD consortium. For more information, see: https://doi.org/10.1038/s44220-023-00187-w.
Study Predictors of Remission in Depression to Individual and Combined Treatment
Data Descriptor Paper https://pubmed.ncbi.nlm.nih.gov/39187625
https://doi.org/10.1186/1745-6215-13-106
DUA Please contact Dr. Christos Davatzikos to obtain the DUA for the derived data and request an introduction to the study PI to obtain the DUA for the raw data.
Country/Region USA
Disease Tag depression
Age (mean ± SD) 38.6 ± 10.9
Age Range 19-64
% Female 53.3
CUBIC Project /cbica/projects/MultisiteMD
PI for CUBIC Access Approval Christos Davatzikos
N Subjects 122
N MR Sessions 122
DLMUSE
(122/122 complete)
/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/PReDICT/Results/PReDICT_DLMUSE_Volumes.csv
RAVENS (DRAMMS-1.4.1)
(121/121 complete)
/cbica/projects/MultisiteMD/Pipelines/CoordinateMD_3.5D_2020/Protocols/RAVENS/PReDICT
Non-Imaging Data

Contact Mathilde Antoniades to request access to the non-imaging data.

/cbica/home/harmang/for_others/final_combined_istaging_withMUSE.csv

Data consolidated and harmonized in 2026.

This study: subset with df[df.Study == 'PReDICT']


Funding
Funding for the study derives from two grants from the National Institute of Mental Health. A Centers for Intervention Development and Applied Research (CIDAR) grant (P50 MH077083; PI: Helen Mayberg, MD) established the center and provided funds to assess participants for predictors of acute response. A subsequent grant (RO1 MH080880; PI: W Edward Craighead, PhD) provided funding to treat non-remitters to the first treatment with combination medication and psychotherapy, to allow follow-up of patients for up to two years to identify predictors of recurrence, and to add patients to the sample to adequately power these studies.

Additional support was received from PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources, PHS Grant M01 RR0039 from the General Clinical Research Center program, and K23 MH086690 (BWD). Forest Labs and Elli Lilly Inc donated the study medications, escitalopram and duloxetine, respectively, and are otherwise uninvolved in study design, data collection, or data analysis, or interpretation of findings.